A remedy that shows a effectiveness to reduce the effects of food allergy in children

The drug “Akezolier”, which is used to treat asthma, has shown effectiveness in the prevention of allergies associated with different types of food, according to a recent study published by the “New England Journal of Medicine” on Sunday. Food allergy affects about 8% of children and 10% of adults, and some of their common causes, such as peanuts, milk, eggs and wheat, are present in many foods, making daily activities, such as attending parties and eating food for patients in restaurants. People with severe allergies receive tips to avoid foods that contain their allergens completely, as these foods can lead to death. According to what was said in the “New Angeland” patrol, the drug “omalizomab”, which is the scientific name “akelerer”, can make the lives of children with food allergies safer by preventing serious allergic reactions to small amounts of allergic foods. It can protect the regular use of Omalizomab to protect people from severe allergic reactions, such as the problems with breathing, which can accidentally produce if they eat a small amount of food that has an allergy to it, according to the study conducted by scientists at the University of Stanford Medical College. “Sharon Shinthra,” acting associate professor of medicine and pediatrics, and the acting director of the ‘Sean Inn Parker’, said that ‘the new medicine really has great reactions to many foods that cause allergies.’ The study showed that “Omalismab” can form a protection layer against small exposure, as patients affected by food allergies face a daily threat of reactions due to accidental exposure. The US Food and Drug Administration (FDA) originally agreed to treat “nalizomab” to treat diseases such as chronic allergic asthma, as it is associated with antibodies that cause many types of allergic diseases and impede their activity. Based on the data collected in the new study, FDA agreed to the medicine “Omalizomab” to reduce the risk of food allergies on February 16. Xinthra notes that many patients with nutritional allergies also suffer from other allergies treated by ‘omalismab’, such as asthma and allergic rhinitis, and thus the treatment can improve all cases. All the study participants had a serious sensitivity to peanuts and at least two other foods. After 4 months of “omalizomab” monthly or every two months, two -thirds of the 118 participants take the drug safely with small amounts of allergens. It is noteworthy that 38.4% of study participants were smaller than 6 years, and it is a lifetime of great risk due to the casual swallow of allergic foods. Food allergies cause significant social and psychological consequences, including the threat of allergic reactions to accidental exposure, some of which can threaten life, and families also have economic consequences due to the purchase of expensive food to avoid allergens. Details of the study and “omalizomab” are an anti -injection body, and connect and disrupt all types of immunoglobulin (the molecule that causes allergies in the blood). So far, the ‘Omisismab’ seems to be able to provide comfort from the multiple food allergens. The study included 177 children suffering from at least 3 food allergies, included, 38% of them are between the age of 1 to 5 years, and 37% range from 6 to 11 years, and 24% ranging from the age of 12 years or longer. The participants were tested by the participants’ tingling, as their bodies interacted with allergic reactions with less than 100 mg of peanut protein and less than 300 milligrams of each other. Two -thirds of the participants were randomly appointed to receive a Nalizomab injection, while a third received a false injection. 79 patients (66.9%) who took ‘omalizomab’ could carry at least 600 milligrams of peanut protein, which is the amount in two or three peanuts, compared to only 4 patients (6.8%) who took the placebo. Similar relationships of patients have shown an improvement in their reactions to other foods in the study. About 80% of patients who consumed ‘omalizumab’ have managed to consume small amounts of at least one food that causes allergies without an allergic reaction, while 69% of patients could eat small amounts of two allergens, and 47% of small amounts of allergic foods. Omalizumab did not cause any side effects except for some minor interactions on the injection site. This study represents the first time that the safety of the drug has been evaluated in children who are no more than one age. Innovative answers have said that more research is needed to understand how to help ‘Omalismab’ for people with food allergies. There are many questions that have not been answered yet, including “What time should patients take this remedy? Is the immune system permanently changed? All kinds of sitting, and it can be in all years, and it can sit in all all kinds, and it can be in all years.